Table 1.
Patient demographics
| Variable | D/R serology, N (%) | P value | |||
|---|---|---|---|---|---|
| +/+ | +/− | −/+ | −/− | ||
| Patient related | |||||
| Number of patients | 3253 | 1074 | 2607 | 2535 | |
| Number of centers | 199 | 178 | 199 | 193 | |
| Age, median(range), years | 43 (1-76) | 42 (1-72) | 47 (<1-83) | 43 (1-76) | <.001 |
| Age at transplant, years | <.001 | ||||
| ≤10 | 157 (5) | 97 (9) | 145 (6) | 209 (8) | |
| 11-20 | 362 (11) | 139 (13) | 212 (8) | 262 (10) | |
| 21-30 | 408 (13) | 125 (12) | 288 (11) | 336 (13) | |
| 31-40 | 493 (15) | 135 (13) | 317 (12) | 339 (13) | |
| 41-50 | 618 (19) | 187 (17) | 529 (20) | 515 (20) | |
| 51-60 | 779 (24) | 262 (24) | 674 (26) | 570 (22) | |
| >60 | 436 (13) | 129 (12) | 442 (17) | 304 (12) | |
| Sex | <.001 | ||||
| Male | 1757 (54) | 651 (61) | 1376 (53) | 1538 (61) | |
| Female | 1496 (46) | 423 (39) | 1231 (47) | 997 (39) | |
| Karnofsky score at transplant | <.001 | ||||
| <90 | 916 (28) | 264 (25) | 813 (31) | 672 (27) | |
| ≥90 | 2230 (69) | 779 (73) | 1699 (65) | 1751 (69) | |
| Missing | 107 (3) | 31 (3) | 95 (4) | 112 (4) | |
| Race | <.001 | ||||
| Caucasian | 1866 (57) | 827 (77) | 2126 (82) | 2241 (88) | |
| African American | 192 (6) | 50 (5) | 91 (3) | 52 (2) | |
| Asian/Pacific Islander | 381 (12) | 42 (4) | 65 (2) | 27 (1) | |
| Hispanic | 450 (14) | 106 (10) | 236 (9) | 154 (6) | |
| Other | 321 (10) | 40 (4) | 55 (2) | 39 (2) | |
| Missing | 43 (1) | 9 (<1) | 34 (1) | 22 (<1) | |
| Time from diagnosis to TX, median(range), months | 7 (<1-607) | 7 (<1-275) | 7 (<1-310) | 7 (<1-314) | .189 |
| Time from diagnosis to transplant | .006 | ||||
| 0-5 mo | 1361 (42) | 474 (44) | 1140 (44) | 1163 (46) | |
| 6-11 mo | 839 (26) | 264 (25) | 599 (23) | 543 (21) | |
| 12-17 mo | 316 (10) | 106 (10) | 291 (11) | 259 (10) | |
| 18-24 mo | 208 (6) | 55 (5) | 179 (7) | 166 (7) | |
| ≥24 mo | 525 (16) | 171 (16) | 387 (15) | 393 (16) | |
| Missing | 4 (<1) | 4 (<1) | 11 (<1) | 11 (<1) | |
| Disease related | |||||
| Disease | <.001 | ||||
| AML | 1816 (56) | 583 (54) | 1594 (61) | 1317 (52) | |
| ALL | 654 (20) | 246 (23) | 470 (18) | 513 (20) | |
| CML | 436 (13) | 114 (11) | 211 (8) | 318 (13) | |
| MDS | 347 (11) | 131 (12) | 332 (13) | 387 (15) | |
| Disease risk at transplant | .006 | ||||
| Low | 1755 (54) | 599 (56) | 1317 (51) | 1388 (55) | |
| Intermediate | 706 (22) | 253 (24) | 603 (23) | 531 (21) | |
| High | 785 (24) | 222 (21) | 684 (26) | 612 (24) | |
| Missing | 7 (<1) | 0 | 3 (<1) | 4 (<1) | |
| Transplant related | |||||
| CMV reactivation in blood by 1 year | <.001 | ||||
| No | 2211 (68) | 958 (89) | 1763 (68) | 2432 (96) | |
| Yes | 1032 (32) | 115 (11) | 841 (32) | 99 (4) | |
| Missing | 10 (<1) | 1 (<1) | 3 (<1) | 4 (<1) | |
| Time from TX to CMV reactivation in blood, median (range), days | 41 (1-359) | 46 (7-235) | 38 (1-362) | 45 (6-350) | .003 |
| Graft type | <.001 | ||||
| Bone marrow | 858 (26) | 302 (28) | 604 (23) | 711 (28) | |
| Peripheral blood | 2395 (74) | 772 (72) | 2003 (77) | 1824 (72) | |
| Donor/recipient HLA match | <.001 | ||||
| HLA-identical siblings | 1816 (56) | 428 (40) | 856 (33) | 971 (38) | |
| Other related | 199 (6) | 61 (6) | 106 (4) | 115 (5) | |
| Well-matched unrelated | 800 (25) | 386 (36) | 1190 (46) | 1105 (44) | |
| Partially matched unrelated | 316 (10) | 158 (15) | 357 (14) | 283 (11) | |
| Mismatched unrelated | 115 (4) | 38 (4) | 89 (3) | 51 (2) | |
| Unrelated (HLA match information missing) | 7 (<1) | 3 (<1) | 9 (<1) | 9 (<1) | |
| Missing | 0 | 0 | 0 | 1 (<1) | |
| Conditioning regimen intensity | <.001 | ||||
| MA | 2421 (74) | 809 (75) | 1940 (74) | 2001 (79) | |
| Non-MA/RIC | 827 (25) | 265 (25) | 667 (26) | 532 (21) | |
| Missing | 5 (<1) | 0 | 0 | 2 (<1) | |
| ATG/CAMPATH as conditioning or GVHD prophylaxis | <.001 | ||||
| ATG + CAMPATH | 0 | 0 | 1 (<1) | 0 | |
| ATG alone | 735 (23) | 262 (24) | 703 (27) | 631 (25) | |
| CAMPATH alone | 116 (4) | 58 (5) | 113 (4) | 82 (3) | |
| No ATG or CAMPATH | 2395 (74) | 752 (70) | 1789 (69) | 1822 (72) | |
| Missing | 7 (<1) | 2 (<1) | 1 (<1) | 0 | |
| GVHD prophylaxis | <.001 | ||||
| Both in vivo and ex vivo | 62 (2) | 27 (3) | 46 (2) | 63 (2) | |
| In vivo only | 789 (24) | 293 (27) | 771 (30) | 650 (26) | |
| Ex vivo only | 112 (3) | 28 (3) | 61 (2) | 82 (3) | |
| Post TX cyclophosphamide + others | 19 (<1) | 12 (1) | 18 (<1) | 27 (1) | |
| FK506 + MMF +- others | 190 (6) | 82 (8) | 220 (8) | 194 (8) | |
| FK506 + MTX +- others (except MMF) | 840 (26) | 309 (29) | 848 (33) | 792 (31) | |
| FK506 + others (except MTX, MMF) | 152 (5) | 48 (4) | 116 (4) | 99 (4) | |
| CSA + MMF +- others (except FK506) | 120 (4) | 36 (3) | 81 (3) | 81 (3) | |
| CSA + MTX +- others (except FK506, MMF) | 856 (26) | 200 (19) | 391 (15) | 462 (18) | |
| CSA + others (except FK506, MTX, MMF) | 72 (2) | 24 (2) | 38 (1) | 55 (2) | |
| Other GVHD prophylaxis | 41 (1) | 15 (1) | 17 (<1) | 30 (1) | |
| aGVHD | |||||
| 0-I | 2075 (64) | 652 (61) | 1580 (61) | 1525 (60) | |
| II-IV | 1143 (35) | 411 (38) | 1004 (39) | 981 (39) | |
| Missing | 35 (1) | 11 (1) | 23 (<1) | 29 (1) | |
| Time from TX to aGVHD, median (range), months | 1 (<1-22) | 1 (<1-6) | 1 (<1-6) | 1 (<1-29) | |
| cGVHD | |||||
| No | 1755 (54) | 527 (49) | 1345 (52) | 1250 (49) | |
| Yes | 1418 (44) | 523 (49) | 1206 (46) | 1230 (48) | |
| Missing | 80 (2) | 24 (2) | 56 (2) | 55 (2) | |
| Time from TX to cGVHD, median (range), months | 5 (2-68) | 6 (2-51) | 5 (2-72) | 6 (2-49) | |
| Year of transplant | <.001 | ||||
| 2003 | 336 (10) | 73 (7) | 148 (6) | 143 (6) | |
| 2004 | 387 (12) | 83 (8) | 183 (7) | 202 (8) | |
| 2005 | 444 (14) | 111 (10) | 236 (9) | 255 (10) | |
| 2006 | 457 (14) | 165 (15) | 355 (14) | 346 (14) | |
| 2007 | 332 (10) | 138 (13) | 379 (15) | 344 (14) | |
| 2008 | 547 (17) | 199 (19) | 467 (18) | 518 (20) | |
| 2009 | 438 (13) | 181 (17) | 498 (19) | 439 (17) | |
| 2010 | 312 (10) | 124 (12) | 341 (13) | 288 (11) | |
| Median follow-up of survivors, months | 61 (1-125) | 59 (3-121) | 60 (2-127) | 60 (3-124) | |
The Pearson χ2 test was used for comparing discrete variables; the Kruskal-Wallis test was used for comparing continuous variables. FK506, tacrolimus; MMF, mycophenolate mofetil; TBI, total body irradiation; TX, transplant.